Biswas Silpak, Raoult Didier, Rolain Jean-Marc
Unité des Rickettsies, CNRS UMR 6020, IFR 48, Faculté de Médecine et de Pharmacie, Université de la Méditerranée, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France.
J Antimicrob Chemother. 2007 Jun;59(6):1065-70. doi: 10.1093/jac/dkm105. Epub 2007 Apr 21.
Bartonella bacilliformis is the aetiological agent of Carrion's disease. Although ciprofloxacin, rifampicin and erythromycin have been successfully used in the treatment of the disease, failures and relapses have been reported. The objective of our study was to select in vitro mutants resistant to antibiotics in order to determine the frequency of mutations and to characterize the mechanism of resistance at the molecular level.
Antibiotic-resistant mutants were selected by serial passages of bacteria on blood agar plates containing antibiotics. Candidate genes involved in resistance were amplified and sequenced and compared in order to look at mutations associated with antibiotic resistance.
Ciprofloxacin-, rifampicin- and erythromycin-resistant mutants were obtained after five, three and four passages, respectively. Conversely, no mutant was obtained with either gentamicin or doxycycline even after 16 passages. The ciprofloxacin mutant contained an amino acid change at position 87 (Asp --> Asn) in its quinolone resistance-determining region of the DNA gyrase protein, whereas the rifampicin-resistant strain had an amino acid change at position 531 (Ser --> Phe) in the rifampicin resistance-determining region of the rpoB gene. Similarly, the erythromycin-resistant mutant showed an A2058G mutation in the 23S rRNA gene.
According with the current knowledge on the treatment of human bartonellosis, we believe that doxycycline in association with gentamicin may be the preferred regimen for the treatment of the acute and eruptive stages of Carrion's disease, but clinical trials are warranted to support our findings.
杆菌状巴尔通体是卡里翁病的病原体。尽管环丙沙星、利福平和红霉素已成功用于治疗该疾病,但仍有治疗失败和复发的报道。我们研究的目的是筛选出对抗生素耐药的体外突变体,以确定突变频率并在分子水平上表征耐药机制。
通过在含有抗生素的血琼脂平板上连续传代细菌来筛选抗生素耐药突变体。对参与耐药的候选基因进行扩增、测序和比较,以观察与抗生素耐药相关的突变。
分别在传代5次、3次和4次后获得了对环丙沙星、利福平及红霉素耐药的突变体。相反,即使传代16次后,用庆大霉素或强力霉素均未获得突变体。环丙沙星突变体在DNA旋转酶蛋白的喹诺酮耐药决定区第87位氨基酸发生改变(天冬氨酸→天冬酰胺),而利福平耐药菌株在rpoB基因的利福平耐药决定区第531位氨基酸发生改变(丝氨酸→苯丙氨酸)。同样,红霉素耐药突变体在23S rRNA基因中出现A2058G突变。
根据目前关于人类巴尔通体病治疗的知识,我们认为强力霉素联合庆大霉素可能是治疗卡里翁病急性和发疹期的首选方案,但需要临床试验来支持我们的发现。